The FDA has accepted for review the New Drug Application for plozasiran for the treatment for familial chylomicronemia syndrome.

This new tool, known as minimal, versatile genetic perturbation technology (mvGPT), combines the powers of gene editing, ...

With its International Headquarters in Zug, Switzerland, Alnylam has become a key part of the Swiss biotech environment.

The China-based cancer drug developer’s offering will fund testing of medicines for several blood malignancies — one of which is part of an alliance with Takeda.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR), a biopharmaceutical company with a market capitalization of $2.68 billion ...

In this review of RNA therapies, we paint an overview of what’s going on in a field that is addressing a number of diseases.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 10, 2025, at 4:30 p.m. ET to discuss its financial results for the fiscal ...

The biotech said it has dosed the first participant in a Phase 3 study of its in vivo gene editing treatment. Elsewhere, the FDA imposed a hold on Atara and lifted another on Amylyx.

引言近年来，单细胞RNA测序技术（scRNA-seq）在揭示复杂生物系统和探索遗传学及临床研究中取得了突破性进展。然而，仅依赖单一的转录组信息往往难以区分分子相似但功能差异显著的细胞类别。因此，融合多种模态信息的单细胞测序技术逐渐成为研究热点，通过同时获取单个细胞的多维数据，研究人员能够更全面地解析细胞状态及其 ...

This is a useful study that seeks to address the role of the TET family of DNA demethylation enzymes in pancreatic beta cell senescence in the context of type 2 diabetes (T2DM). Although the concepts ...

The authors examine the role of Numb, a Notch inhibitor, in intestinal stem cell self-renewal in Drosophila during homeostasis and regeneration. This is an important study providing evidence of a Numb ...